Inmune Bio, Inc. (INMB): Total Assets
$32.35M
As of 2025-12-31
$26.84M
As of 2026-06-30
-26.6%
3-year compound annual growth
-4.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.35M | -18.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $39.56M | -30.6% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $57.00M | -30.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $81.80M | -18.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $99.94M | +145.8% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $40.66M | +66.1% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $24.47M | +40.9% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $17.36M | -5.7% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $18.41M | n/a | 2019-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $32.35M | -18.2% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $15.99M | +70.3% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $51.22M | -47.6% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $1.64M | +195.7% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $93.00M | -4.0% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $7.81M | +17.1% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗